Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
Medpage Today on MSN22h
Pulled Myeloma Drug Improves Survival in TrialA significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...
The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...
2d
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...
A bispecifics can unseat Keytruda. | BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial ...
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...
Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback